|
|
Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Jean-Baptiste Fraison
,
Arsène Mekinian
,
Eric Grignano
,
Jean-Emmanuel Kahn
,
Jean-Benoit Arlet
,
et al.
Journal articles
hal-01278608v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome
Sabrina Bondu
,
Anne-Sophie Alary
,
Carine Lefevre
,
Alexandre Houy
,
Grace Jung
,
et al.
Journal articles
inserm-02449216v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes
Meunier Mathieu
,
Chloé Friedrich
,
Nicolas Ducrot
,
Johanna Zannoni
,
Tondeur Sylvie
,
et al.
Journal articles
inserm-03874959v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Gandhi Damaj
,
Rémy Gressin
,
Krimo Bouabdallah
,
Guillaume Cartron
,
Bachra Choufi
,
et al.
Journal articles
inserm-00868869v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Gandhi Damaj
,
Alain Duhamel
,
Marie Robin
,
Yves Beguin
,
Mauricette Michallet
,
et al.
Journal articles
inserm-00821506v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
Sophie Park
,
Olivier Kosmider
,
Fréderic Maloisel
,
Bernard Drénou
,
Nicolas Chapuis
,
et al.
Journal articles
hal-02351432v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|